Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Robinhood Markets, Inc. (HOOD) vs Heron Therapeutics Inc (HRTX) Price & Performance

Robinhood Markets, Inc.Trade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Robinhood Markets, Inc. vs Heron Therapeutics Inc — how do they compare? Robinhood Markets, Inc. trades at $94.2 (market cap $84.86B), while Heron Therapeutics Inc trades at $0.35 (market cap $61.47M). The key difference: Robinhood Markets, Inc. is far larger — about 1380.5× Heron Therapeutics Inc's market cap, and Robinhood Markets, Inc. is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

HOODHRTX
Market Cap
$84.86B$61.47M
Sector
TechnologyHealth
52-Week High
$152.46$1.49
52-Week Low
$65.16$0.32
Enterprise Value
$91.40B$168.21M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Robinhood Markets, Inc.

Robinhood Markets (HOOD) trades at $94.40, down 0.13% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust Q2 2026 results with revenue growth of 32% and earnings beating expectations, driven by diversification beyond crypto into event contracts and international expansion. Valuation metrics remain elevated with P/E of 41.76 and P/S of 17.6, reflecting premium pricing for growth prospects.

The outlook remains positive with analyst consensus pointing to significant upside (target $123.46), though near-term technical weakness and competitive pressures in the UK crypto expansion present risks. Revenue diversification and strong cash flow generation support long-term growth, but investors should monitor execution on international expansion and margin sustainability amid high valuations.

Heron Therapeutics Inc

HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.

The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Robinhood Markets, Inc.

Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.

Read more on HOOD

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX